Swiss National Bank Ocugen, Inc. Transaction History

Swiss National Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$1.11 - $1.87 $16,983 - $28,611	15,300 Added 3.01%	522,900 $679,000
Q2 2022 Aug 09, 2022	BUY	$1.83 - $3.45 $66,978 - $126,270	36,600 Added 7.77%	507,600 $1.15 Million
Q1 2022 May 09, 2022	BUY	$2.34 - $4.72 $77,220 - $155,760	33,000 Added 7.53%	471,000 $1.55 Million
Q3 2021 Nov 08, 2021	BUY	$6.36 - $8.51 $148,824 - $199,134	23,400 Added 5.64%	438,000 $3.15 Million
Q2 2021 Aug 06, 2021	BUY	$5.52 - $15.68 $2.29 Million - $6.5 Million	414,600 New	414,600 $3.33 Million

124

78.3M

535K

523K

Ticker OCGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,566,000
Market Cap $167M
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.